Senate Democrats press AstraZeneca, Sanofi on RSV antibody shortage
As RSV cases start to rise this season, AstraZeneca and Sanofi have struggled to match the demand for their new monoclonal antibody to protect against RSV — and several Democrat senators are asking the two companies to explain what’s causing the supply holdup.
The FDA in July approved the two companies’ Beyfortus (nirsevimab), and the CDC recommended it be used for infants at the highest risk for severe RSV cases, including young infants under the age of six months, and infants with underlying conditions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.